KPE-00001113

KPE-00001113 is an experimental small molecule compound developed by Kemin Pharma, a division of Kemin Industries. The compound was part of a portfolio of anti-inflammatory, anti-bacterial, and anti-viral candidates acquired by Kemin through its 2009 acquisition of Amalyte Pharmaceuticals. Kemin Pharma's research into the KPE series has primarily focused on the treatment of inflammatory conditions, with a specific emphasis on gastrointestinal health and inflammatory bowel disease (IBD). While the compound is identified in pharmaceutical databases as a potential therapeutic agent, detailed information regarding its specific molecular target, mechanism of action, and clinical development progress remains proprietary and is not publicly disclosed in detail.